



DBV Technologies to Present at Upcoming US Investors Conferences

BAGNEUX, France, June 16, 2014 - DBV Technologies, (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin[®], a new paradigm for the treatment of food allergies, today announced that members of the company's management team will present at two upcoming investors conferences in New York City, USA, in June.

- Pierre-Henri Benhamou, Chairman and Chief Executive Officer, David Schilansky, Chief Financial Officer, and Charles Ruban, Chief Development Officer, will present at the JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 3:30 p.m. E.T. in New York, NY.
- Pierre-Henri Benhamou, Chairman and Chief Executive Officer, will present at the French Life Sciences Day on Thursday, June 26, 2014 at 9:15 a.m. E.T. in New York, NY.

About DBV Technologies

DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin[®] technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company's significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin[®] Peanut and Viaskin[®] Milk. The clinical development program for Viaskin[®] Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin[®] patch for young children with house dust mite allergy – a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

CAUTION: Viaskin[®] is not approved for sale in the USA.

Viaskin[®] and EPIT[™] are registered trademarks of DBV Technologies, SA

DBV Technologies Contacts

David Schilansky

Chief Financial Officer

Tel. : +33(0)1 55 42 78 75

david.schilansky@dbv-technologies.com

Susanna Mesa

VP Finance, US Investor Relations & Strategy

Tel. : +1 917-346-3447

susanna.mesa@dbv-technologies.com

Nathalie Donne

Director, Business Development & Corporate Communications

Tel. : +33(0)1 55 42 78 72

nathalie.donne@dbv-technologies.com



DBV IR and Media Contacts

Todd James

U.S. Investor Relations
The Trout Group
Tel. : +1 646-378-2926
tjames@troutgroup.com

BMC Communications

Media Relations
Brad Miles
Tel. : +1 646-513-3125
brad@bmccommunications.com